Contact
searchSearch
HMP Global
Quiz

Making Sense of HECSI Scores in Trials

Riya Gandhi, MA
07/15/2025

Related Content

hand eczema
News
Delgocitinib Cream Demonstrates Consistent Efficacy in Chronic Hand Eczema Regardless of Prior Systemic Therapy
04/01/2026
Riya Gandhi, MA
Phase 3 pooled analysis shows significant improvements in disease severity, itch, and pain across both systemic-naïve and experienced patients.
Phase 3 pooled analysis shows significant improvements in disease severity, itch, and pain across both systemic-naïve and experienced patients.
Phase 3 pooled analysis shows...
04/01/2026
The Dermatologist
Guttman
Videos
Chronic Hand Eczema: Pathways and Emerging Therapies
04/01/2026
Riya Gandhi, MA
Dr Emma Guttman explains how chronic hand eczema is now understood as a heterogeneous disease driven by different immune pathways depending on underlying causes.
Dr Emma Guttman explains how chronic hand eczema is now understood as a heterogeneous disease driven by different immune pathways depending on underlying causes.
Dr Emma Guttman explains how...
04/01/2026
The Dermatologist
NEA Approved Features
Supporting the Transition to Self-Managed Care in Adolescents and Young Adults With Atopic Dermatitis
03/09/2026
Allison Loiselle, PhD; Jessica Garlewicz
The National Eczema Association offers practical guidance on assessing transition readiness and empowering adolescents and young adults as they move toward independent atopic dermatitis care.
The National Eczema Association offers practical guidance on assessing transition readiness and empowering adolescents and young adults as they move toward independent atopic dermatitis care.
The National Eczema Association...
03/09/2026
The Dermatologist
Dr Guttman
Conference Coverage
Chronic Hand Eczema: From Pathogenic Subtypes to Targeted JAK and IL-4/13 Therapy
02/20/2026
Riya Gandhi, MA
A clinical update on chronic hand eczema, highlighting delgocitinib cream, ruxolitinib, gusacitinib, dupilumab, tralokinumab, and biomarker-driven Th1/Th2/Th17 endotypes.
A clinical update on chronic hand eczema, highlighting delgocitinib cream, ruxolitinib, gusacitinib, dupilumab, tralokinumab, and biomarker-driven Th1/Th2/Th17 endotypes.
A clinical update on chronic...
02/20/2026
The Dermatologist

Popular Articles

Shawn Kwatra, MD
Conference Coverage
Expert Insights: Complex Dermatology Cases
05/09/2024
Jessica Garlewicz
The final session on the first day of Spring Dermatology Week 2024, saw Shawn Kwatra, MD; Joseph Merola, MD, MMSc, FAAD, FACR; Mital Patel-Cohen, MD; and Vishal Patel, MD, discuss their latest case reports in, “Complex Dermatology Cases.”
The final session on the first day of Spring Dermatology Week 2024, saw Shawn Kwatra, MD; Joseph Merola, MD, MMSc, FAAD, FACR; Mital Patel-Cohen, MD; and Vishal Patel, MD, discuss their latest case reports in, “Complex Dermatology Cases.”
The final session on the first...
05/09/2024
The Dermatologist
AD
News
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis
06/13/2024
Riya Gandhi, MA
A recent study has shed light on the efficacy and safety of ruxolitinib cream among adolescents grappling with atopic dermatitis.
A recent study has shed light on the efficacy and safety of ruxolitinib cream among adolescents grappling with atopic dermatitis.
A recent study has shed light on...
06/13/2024
The Dermatologist
Clinical Insights
The Risk of Keratinocyte Cancer in Patients With Vitiligo
08/05/2024
Riya Gandhi, MA
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and...
08/05/2024
The Dermatologist
atopic dermatitis
FDA Alerts
Lebrikizumab FDA Approved for Moderate to Severe Atopic Dermatitis in Adults and Children
09/16/2024
Jessica Garlewicz
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
The US Food and Drug...
09/16/2024
The Dermatologist
The ElderDerm: Episode 3, Shared- Decision Making
Podcasts
The ElderDerm: Episode 3, Shared-Decision Making
05/16/2024
Adam Friedman, MD; Jaya Manjunath
In our next segment of the ElderDerm Podcast, listen to co-hosts Dr Adam Friedman and Jaya Manjunath discuss what shared decision-making is, and why it is important in dermatology.
In our next segment of the ElderDerm Podcast, listen to co-hosts Dr Adam Friedman and Jaya Manjunath discuss what shared decision-making is, and why it is important in dermatology.
In our next segment of the...
05/16/2024
The Dermatologist
April/May 2026 cover

Current Issue

May 2026
Volume 34
Issue 3
Current Issue
Issue Archive

Latest Quizzes and Trivia

Quiz
Predicting Disease Severity and Persistence in Pediatric Atopic Dermatitis
04/15/2026
Riya Gandhi, MA
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in...
04/15/2026
The Dermatologist
Quiz
Type 2 Inflammation and Early Systemic Therapy in Pediatric Atopic Dermatitis
04/05/2026
Riya Gandhi, MA
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical...
04/05/2026
The Dermatologist
Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist
Quiz
Rethinking Severity and JAK Inhibitor Strategy in Alopecia Areata
03/12/2026
Riya Gandhi, MA
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine...
03/12/2026
The Dermatologist
Quiz
Cytokine Hierarchy and Sustained Pruritus in PN
03/10/2026
Riya Gandhi, MA
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and...
03/10/2026
The Dermatologist
Quiz
Type 2 Inflammation as a Pathogenic Driver in Prurigo Nodularis
03/05/2026
Riya Gandhi, MA
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how...
03/05/2026
The Dermatologist
psoriasis
Quiz
Distinguishing Feature of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing...
03/02/2026
The Dermatologist
psoriasis
Quiz
Quiz: Misdiagnosis of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized...
03/02/2026
The Dermatologist
Quiz
Allergic Disease Progression: Genetics and Environment
02/26/2026
Riya Gandhi, MA
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between...
02/26/2026
The Dermatologist
Quiz
Early Intervention Strategies in Pediatric Atopic Dermatitis
02/26/2026
Riya Gandhi, MA
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of...
02/26/2026
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use